Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Anti-HEV Assays Evaluated for Diagnosing Acute Hepatitis E Infections

By LabMedica International staff writers
Posted on 04 Dec 2013
The performance of two anti-HEV IgG and IgM assays were assessed for diagnosing acute HEV infections in immunocompromised patients.

Hepatitis E virus is an emerging concern in immunocompromised patients, who may become chronically infected. More...
No data were available for immunocompromised patients, who might not mount a good antibody response to HEV and might thus test negative for anti-HEV antibodies. The two anti-HEV assays evaluated in the study, published in the Journal of Clinical Virology online ahead of print October 15, 2013, were those from Adaltis and Wantai, the two main serological assays employed in Europe, specifically: EIAgen HEV IgG and IgM kits (Adaltis; Eurobio, France), based on synthetic antigens encoded by the ORF2 and ORF3 genes of HEV1 and HEV2; and the HEVIgM and IgG ELISA 3.0 Wantai kits (Wantai Biological Pharmacy Enterprise Co.; China), based on a recombinant HEV1 antigen, pE2. Tests were performed as recommended by the manufacturers.

Specificities were estimated by testing samples from 2 to 3 year-old children and blood donors and sensitivities were estimated by testing 40 immunocompromised patients acutely infected. Both anti-HEV IgM assays were highly specific (99.6% and 100%). The sensitivity of the Adaltis was 87.5%, and that of Wantai was 85%. The specificities of anti-HEV IgG Wantai (97.8%) and Adaltis tests (89.5%, = 0.1) were similar but the Wantai test was more sensitive (45%) than the Adaltis test (15%, < 0.001). None of the samples was anti-HEV IgM negative and IgG positive.

The authors, led by Dr. Florence Abravanel of the Centre Hospitalier Universitaire de Toulouse (University Hospital Center of Toulouse; Toulouse, France), concluded that these anti-HEV IgM assays performed well in immunosuppressed patients with acute hepatitis E and can be used as first line virological tools. Testing for anti-HEV IgG and IgM simultaneously at the acute phase did not improve the diagnostic performance. In contrast, molecular detection of HEV RNA appears essential to exclude an HEV infection in patients who are negative for anti-HEV IgM and to assess the evolution of hepatitis E three months thereafter.

Related Links:

Centre Hospitalier Universitaire de Toulouse



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.